ImmunoGen, Inc. (NASDAQ:IMGN) VP Anna Berkenblit sold 5,851 shares of the company’s stock in a transaction dated Monday, September 10th. The shares were sold at an average price of $9.46, for a total value of $55,350.46. Following the completion of the transaction, the vice president now owns 138,620 shares in the company, valued at approximately $1,311,345.20. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Shares of NASDAQ IMGN opened at $9.26 on Friday. The company has a market capitalization of $1.39 billion, a P/E ratio of -12.35 and a beta of 1.95. ImmunoGen, Inc. has a 52 week low of $4.80 and a 52 week high of $13.41. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.76 and a quick ratio of 5.73.

ImmunoGen (NASDAQ:IMGN) last announced its quarterly earnings results on Friday, July 27th. The biotechnology company reported ($0.31) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.29) by ($0.02). The company had revenue of $9.29 million during the quarter, compared to analyst estimates of $14.12 million. The business’s quarterly revenue was down 76.2% compared to the same quarter last year. During the same period last year, the firm posted ($0.10) earnings per share. equities analysts forecast that ImmunoGen, Inc. will post -1.19 earnings per share for the current year.

A number of equities analysts have recently weighed in on IMGN shares. Zacks Investment Research downgraded ImmunoGen from a “hold” rating to a “sell” rating in a report on Thursday, August 2nd. BidaskClub upgraded ImmunoGen from a “sell” rating to a “hold” rating in a report on Thursday, August 23rd. Piper Jaffray Companies began coverage on ImmunoGen in a research note on Thursday, September 6th. They issued an “overweight” rating for the company. ValuEngine cut ImmunoGen from a “strong-buy” rating to a “buy” rating in a research note on Thursday, June 28th. Finally, HC Wainwright set a $18.00 price target on ImmunoGen and gave the company a “buy” rating in a research note on Thursday, May 17th. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $12.42.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. SG Americas Securities LLC bought a new stake in ImmunoGen during the second quarter worth approximately $115,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in ImmunoGen by 198.5% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,144 shares of the biotechnology company’s stock worth $117,000 after purchasing an additional 7,411 shares during the period. Quantitative Systematic Strategies LLC bought a new stake in ImmunoGen during the first quarter worth approximately $126,000. Private Advisor Group LLC bought a new stake in ImmunoGen during the second quarter worth approximately $131,000. Finally, Great West Life Assurance Co. Can boosted its position in ImmunoGen by 75.1% during the second quarter. Great West Life Assurance Co. Can now owns 15,767 shares of the biotechnology company’s stock worth $153,000 after purchasing an additional 6,763 shares during the period. 83.77% of the stock is owned by institutional investors and hedge funds.

About ImmunoGen

ImmunoGen, Inc, a clinical-stage biotechnology company, focuses on developing antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; IMGN779 that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm, as well as coltuximab ravtansine, a CD19-targeting ADC, which is in Phase II trial for DLBCL.

Read More: What is a Fiduciary?

Insider Buying and Selling by Quarter for ImmunoGen (NASDAQ:IMGN)

Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.